Cardax, Inc. (CDXI) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CDXI representa a Cardax, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Cardax, Inc. (CDXI) Resumen de Asistencia Médica y Tuberías
Cardax, Inc. is a biopharmaceutical company developing and commercializing dietary supplements and pharmaceuticals targeting inflammatory health. Its primary product, ZanthoSyn, an astaxanthin supplement, is sold through e-commerce and wholesale channels. The company's pharmaceutical pipeline includes CDX-101 for cardiovascular inflammation and CDX-301 for macular degeneration, positioning it within the competitive biotechnology landscape.
Tesis de Inversión
Cardax, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on inflammation and oxidative stress, coupled with its astaxanthin-based product line, aligns with growing consumer and medical interest in natural compounds for health and disease management. Key value drivers include the successful commercialization of ZanthoSyn, which currently has a gross margin of 63.6%, and the advancement of CDX-101 and CDX-301 through clinical trials. Growth catalysts include potential partnerships for pharmaceutical development and regulatory approvals for its drug candidates. However, the company's negative profit margin of -938.0% and reliance on e-commerce and wholesale channels for ZanthoSyn sales pose significant risks. The company's small market capitalization of $0.00B and high beta of -13.76 indicate substantial volatility. Successful navigation of regulatory hurdles and securing additional funding will be critical for Cardax to realize its potential.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 63.6% on ZanthoSyn sales indicates strong pricing power and efficient production.
- Development of CDX-101 targets severe hypertriglyceridemia, a significant unmet medical need in cardiovascular health.
- CDX-301 is being developed for macular degeneration, addressing a growing market driven by an aging population.
- ZanthoSyn is sold through e-commerce and wholesale channels, providing diversified revenue streams.
- The company has a small team of 10 employees, suggesting a lean operational structure.
Competidores y Pares
Fortalezas
- Proprietary astaxanthin formulation (ZanthoSyn).
- Focus on inflammation and oxidative stress.
- Development pipeline of pharmaceutical candidates.
- Existing e-commerce and wholesale distribution channels.
Debilidades
- Small market capitalization.
- Negative profit margin.
- Limited financial resources.
- Reliance on a small number of products.
Catalizadores
- Upcoming: Results from clinical trials for CDX-101.
- Upcoming: Results from clinical trials for CDX-301.
- Ongoing: Expansion of ZanthoSyn distribution channels.
- Ongoing: Potential partnerships with pharmaceutical companies.
- Ongoing: New product development in inflammatory health.
Riesgos
- Potential: Failure to obtain regulatory approvals for CDX-101 and CDX-301.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on a small number of products.
- Potential: Adverse events associated with its products.
Oportunidades de crecimiento
- Expansion of ZanthoSyn Distribution: Cardax can expand its distribution channels for ZanthoSyn beyond e-commerce and wholesale to include retail pharmacies and healthcare providers. This broader reach could significantly increase sales volume and brand awareness. The global dietary supplements market is expected to grow, presenting a substantial opportunity for ZanthoSyn to capture a larger market share. Timeline: Ongoing.
- Advancement of CDX-101 Clinical Trials: Successful completion of clinical trials for CDX-101 would represent a major milestone for Cardax, potentially leading to regulatory approval and commercialization. The market for cardiovascular drugs is substantial, and a novel treatment for severe hypertriglyceridemia could generate significant revenue. The timeline for clinical trials and regulatory approval is estimated to be several years. Market size: Multi-billion dollar market.
- Development of CDX-301 for Macular Degeneration: The development of CDX-301 offers Cardax an opportunity to address the growing market for macular degeneration treatments. As the global population ages, the prevalence of macular degeneration is expected to increase, driving demand for effective therapies. Successful clinical trials and regulatory approval could position CDX-301 as a valuable asset. Timeline: Several years for clinical trials and approval. Market size: Billions of dollars.
- Strategic Partnerships with Pharmaceutical Companies: Cardax can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pharmaceutical candidates. These partnerships could provide access to funding, expertise, and distribution networks. The pharmaceutical industry is actively seeking innovative therapies, making strategic partnerships a viable growth strategy. Timeline: Ongoing.
- Expansion into New Therapeutic Areas: Cardax can leverage its expertise in inflammation and oxidative stress to develop new products and therapies for other chronic diseases. This diversification could reduce the company's reliance on its existing product pipeline and create new revenue streams. The market for chronic disease treatments is vast, offering numerous opportunities for Cardax to expand its focus. Timeline: Long-term.
Oportunidades
- Expansion of ZanthoSyn distribution.
- Successful clinical trials for CDX-101 and CDX-301.
- Strategic partnerships with pharmaceutical companies.
- Expansion into new therapeutic areas.
Amenazas
- Competition from established pharmaceutical companies.
- Regulatory hurdles for pharmaceutical approvals.
- Changes in consumer preferences for dietary supplements.
- Potential adverse events associated with its products.
Ventajas competitivas
- Proprietary formulations of astaxanthin and zeaxanthin.
- Focus on enhanced absorption and purity of ingredients.
- Development of pharmaceutical candidates targeting specific diseases.
- Established e-commerce and wholesale distribution channels for ZanthoSyn.
Acerca de CDXI
Cardax, Inc., based in Honolulu, Hawaii, is a biopharmaceutical company dedicated to creating and marketing innovative dietary supplements and pharmaceuticals designed to combat chronic diseases driven by inflammation and oxidative stress. The company's flagship product, ZanthoSyn, is an inflammatory supplement formulated with astaxanthin, known for its enhanced absorption and purity. ZanthoSyn is currently available through e-commerce platforms and wholesale distribution channels. Founded with the vision of harnessing the therapeutic potential of natural compounds, Cardax is also actively developing a pipeline of pharmaceutical candidates. CDX-101, one of the company's leading pharmaceutical assets, is an astaxanthin-based formulation targeting cardiovascular inflammation and dyslipidemia, with a specific focus on severe hypertriglyceridemia. The company is also advancing CDX-301, a zeaxanthin-based pharmaceutical candidate intended for the treatment of macular degeneration. These pharmaceutical programs represent Cardax's strategic expansion into addressing significant unmet medical needs with innovative, science-backed solutions. Cardax's business model encompasses both the direct-to-consumer sale of dietary supplements and the development of prescription pharmaceuticals, allowing the company to generate revenue while simultaneously pursuing long-term growth opportunities in the pharmaceutical market. With a small team of 10 employees, Cardax is focused on efficiently advancing its product pipeline and expanding its market reach.
Qué hacen
- Develops dietary supplements for inflammatory health.
- Commercializes dietary supplements through e-commerce and wholesale channels.
- Develops pharmaceutical candidates for chronic diseases.
- Focuses on inflammation and oxidative stress.
- Utilizes astaxanthin and zeaxanthin in its products.
- Targets cardiovascular inflammation and macular degeneration.
Modelo de Negocio
- Develops and patents proprietary formulations.
- Sells ZanthoSyn directly to consumers through e-commerce.
- Distributes ZanthoSyn through wholesale channels.
- Seeks partnerships for pharmaceutical development.
Contexto de la Industria
Cardax, Inc. operates within the biotechnology and dietary supplement industries, both characterized by rapid innovation and evolving consumer preferences. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in drug discovery and personalized medicine. The dietary supplement market is also experiencing steady growth, fueled by increasing consumer awareness of preventative healthcare. Cardax competes with both established pharmaceutical companies and smaller biotech firms in the development of novel therapeutics. The company's success depends on its ability to differentiate its products, navigate regulatory pathways, and secure strategic partnerships.
Clientes Clave
- Consumers seeking inflammatory health supplements.
- Wholesale distributors of dietary supplements.
- Potential pharmaceutical partners.
- Patients with cardiovascular inflammation and dyslipidemia.
- Patients with macular degeneration.
Finanzas
Gráfico e información
Precio de la acción de Cardax, Inc. (CDXI): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CDXI.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CDXI.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CDXI.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CDXI en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: David G. Watumull
CEO
David G. Watumull serves as the CEO of Cardax, Inc., leading a team of 10 employees. Information regarding his detailed career history, education, and previous roles is not available. His leadership is focused on guiding the company's strategic direction, overseeing the development and commercialization of its products, and managing its overall operations. He is responsible for driving the company's growth and achieving its financial objectives.
Historial: Due to limited information, David G. Watumull's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. His focus is on advancing the company's pharmaceutical pipeline and expanding the market reach of ZanthoSyn. Further information is needed to evaluate his long-term impact on Cardax, Inc.
Información del mercado OTC de CDXI
The OTC Other tier, where Cardax trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, such as minimum share price or market capitalization requirements. This lack of regulation and oversight increases the risk associated with investing in these companies.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in CDXI.
- Low trading volume and liquidity can lead to price volatility.
- Lack of regulatory oversight on the OTC Other tier.
- Potential for fraud or manipulation in the OTC market.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Analyze the company's capital structure and funding sources.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Development of pharmaceutical candidates (CDX-101 and CDX-301).
- Commercialization of ZanthoSyn through e-commerce and wholesale channels.
- Focus on scientific research and development.
- Company has been in operation for several years.
Preguntas Comunes Sobre CDXI
¿Cuáles son los factores clave para evaluar CDXI?
Cardax, Inc. (CDXI) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Proprietary astaxanthin formulation (ZanthoSyn).. Riesgo principal a monitorear: Potential: Failure to obtain regulatory approvals for CDX-101 and CDX-301.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CDXI?
CDXI actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CDXI?
Los precios de CDXI se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CDXI?
La cobertura de analistas para CDXI incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CDXI?
Las categorías de riesgo para CDXI incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure to obtain regulatory approvals for CDX-101 and CDX-301.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CDXI?
La relación P/E para CDXI compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CDXI sobrevalorada o infravalorada?
Determinar si Cardax, Inc. (CDXI) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CDXI?
Cardax, Inc. (CDXI) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on CEO track record.
- OTC market data may be less reliable than major exchanges.
- AI analysis pending, limiting comprehensive insights.